Actinogen Medical Starts Treatment of Patients in Alzheimer's Disease Trial

MT Newswires Live

Dec 18, 2025

Actinogen Medical (ASX:ACW) started treatment of all 246 patients in the XanaMIA phase 2b/3 Alzheimer's disease trial, and expects final results in November 2026, according to a Thursday filing with the Australian bourse.

The company had earlier expected the results in the fourth quarter, the filing said.

The trial will test whether the drug candidate Xanamem can slow the progression of Alzheimer's disease over 36 weeks in patients taking 10 milligrams of the drug or a placebo once daily, the filing added.

An interim analysis of safety and efficacy futility from the partially completed trial will be conducted in January, the company said.

The final analysis will compare the efficacy and safety of Xanamem with that of patients who received placebo, the company added.

Shares of the company fell 2% in recent Thursday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2592400839"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2592400839\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2592400839?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 09:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592400839","market":"hk","top_or_hot":-1,"title":"Actinogen Medical Starts Treatment of Patients in Alzheimer's Disease Trial","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ACW.AU\">Actinogen Medical</a> (ASX:ACW) started treatment of all 246 patients in the XanaMIA phase 2b/3 Alzheimer's disease trial, and expects final results in November 2026, according to a Thursday filing with the Australian bourse.</p><p>The company had earlier expected the results in the fourth quarter, the filing said.</p><p>The trial will test whether the drug candidate Xanamem can slow the progression of Alzheimer's disease over 36 weeks in patients taking 10 milligrams of the drug or a placebo once daily, the filing added.</p><p>An interim analysis of safety and efficacy futility from the partially completed trial will be conducted in January, the company said.</p><p>The final analysis will compare the efficacy and safety of Xanamem with that of patients who received placebo, the company added.</p><p>Shares of the company fell 2% in recent Thursday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Actinogen Medical Starts Treatment of Patients in Alzheimer's Disease Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nActinogen Medical Starts Treatment of Patients in Alzheimer's Disease Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-18 09:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ACW.AU\">Actinogen Medical</a> (ASX:ACW) started treatment of all 246 patients in the XanaMIA phase 2b/3 Alzheimer's disease trial, and expects final results in November 2026, according to a Thursday filing with the Australian bourse.</p><p>The company had earlier expected the results in the fourth quarter, the filing said.</p><p>The trial will test whether the drug candidate Xanamem can slow the progression of Alzheimer's disease over 36 weeks in patients taking 10 milligrams of the drug or a placebo once daily, the filing added.</p><p>An interim analysis of safety and efficacy futility from the partially completed trial will be conducted in January, the company said.</p><p>The final analysis will compare the efficacy and safety of Xanamem with that of patients who received placebo, the company added.</p><p>Shares of the company fell 2% in recent Thursday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2592400839","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592400839","pubTimestamp":1766022289,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Actinogen Medical  started treatment of all 246 patients in the XanaMIA phase 2b/3 Alzheimer's disease trial, and expects final results in November 2026, according to a Thursday filing with the Australian bourse.The company had earlier expected the results in the fourth quarter, the filing said.The trial will test whether the drug candidate Xanamem can slow the progression of Alzheimer's disease over 36 weeks in patients taking 10 milligrams of the drug or a placebo once daily, the filing added.An interim analysis of safety and efficacy futility from the partially completed trial will be conducted in January, the company said.The final analysis will compare the efficacy and safety of Xanamem with that of patients who received placebo, the company added.Shares of the company fell 2% in recent Thursday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","BK7067":"生物科技","ACW.AU":"ACTINOGEN MEDICAL LTD"},"translate_title":"Actinogen Medical开始治疗阿尔茨海默病试验中的患者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACW.AU":1},"content_text":"Actinogen Medical (ASX:ACW) started treatment of all 246 patients in the XanaMIA phase 2b/3 Alzheimer's disease trial, and expects final results in November 2026, according to a Thursday filing with the Australian bourse.The company had earlier expected the results in the fourth quarter, the filing said.The trial will test whether the drug candidate Xanamem can slow the progression of Alzheimer's disease over 36 weeks in patients taking 10 milligrams of the drug or a placebo once daily, the filing added.An interim analysis of safety and efficacy futility from the partially completed trial will be conducted in January, the company said.The final analysis will compare the efficacy and safety of Xanamem with that of patients who received placebo, the company added.Shares of the company fell 2% in recent Thursday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}